Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Curr Osteoporos Rep. 2020 Jun;18(3):210–227. doi: 10.1007/s11914-020-00570-x

Table 2.

Summary of IGF-1 Antagonists

Antagonist Advantage Disadvantage Citation
Anti-IGF-IR antibodies (i.e. ganitumab and αIR3) Highly specific for the IGF-1R Activates the insulin receptor and promotes unwanted growth; Large molecular weight (145–155kDa); Drug resistance [145,216]
Small-molecule TKIs (i.e. Linsitinib and BMS-754807) Targets both IGF-1R and insulin receptor; Small molecular weight (0.42-0.46kDa) Less specific; Reported toxicity (i.e. diarrhea and myelosuppression); Drug resistance [223–225]
IGF-1 peptide analogs (i.e. JB1, JB2 and JB3) Highly specific for the IGF-1R; Small molecular weight (0.6–1.2kDa); Low toxicity Drug resistance [215–219]